PMID- 15953348
OWN - NLM
STAT- MEDLINE
DCOM- 20050808
LR  - 20181201
IS  - 0022-3042 (Print)
IS  - 0022-3042 (Linking)
VI  - 94
IP  - 1
DP  - 2005 Jul
TI  - Differential monoaminergic, neuroendocrine and behavioural responses after 
      central administration of corticotropin-releasing factor receptor type 1 and type 
      2 agonists.
PG  - 45-56
AB  - Corticotropin-releasing factor (CRF) mediates various aspects of the stress 
      response. To differentiate between the roles of CRF(1) and CRF(2) receptor 
      subtypes in monoaminergic neurotransmission, 
      hypothalamic-pituitary-adrenocortical axis activity and behaviour we compared the 
      effects of CRF and urocortin 1 with those of the selective CRF(2) receptor 
      ligands urocortin 2 and urocortin 3. In vivo microdialysis in the rat hippocampus 
      was used to assess free corticosterone, extracellular levels of serotonin (5-HT) 
      and noradrenaline (NA), and their metabolites 5-hydroxyindoleacetic acid (5-HIAA) 
      and 3-methoxy-4-hydroxyphenylglycol (MHPG), respectively. Intracerebroventricular 
      (i.c.v.) injection of CRF and urocortin 1, 2 and 3 (1.0 microg) increased 
      hippocampal levels of 5-HT and 5-HIAA. CRF and urocortin 1 increased NA and MHPG, 
      whereas urocortin 2 and urocortin 3 elevated MHPG, but not NA levels. CRF and the 
      urocortins induced an immediate increase in behavioural activity. CRF and 
      urocortin 1 mainly caused grooming and exploratory behaviour. In contrast, 
      urocortin 2 and urocortin 3 both induced exploratory behaviour, but not grooming, 
      and increased time spent eating food pellets. All urocortins, but not CRF, 
      suppressed food intake 4-6 h after injection. Hippocampal free corticosterone 
      levels were elevated by CRF, urocortin 1 and 3, but not by urocortin 2. The time 
      courses of the CRF- and urocortin 1-induced responses were significantly 
      prolonged as compared to those of the CRF(2) receptor ligands. The stimulatory 
      changes evoked by CRF and urocortin 1 were present up to 4-6 h after injection, 
      whereas the effects of urocortin 2 and urocortin 3 returned to baseline within 
      2.5 h after injection. Pre-treatment with the selective antagonist 
      antisauvagine-30 (5.0 microg, i.c.v.) confirmed that the effects of urocortin 3 
      were CRF(2) receptor-mediated. The differential time course of the monoaminergic, 
      neuroendocrine and behavioural effects of CRF and urocortin 1, as compared to 
      urocortin 2 and urocortin 3, and the specific behavioural pattern induced by the 
      CRF(2) receptor ligands, suggest a distinct role for CRF(2) receptors in the 
      stress response.
FAU - de Groote, Lotte
AU  - de Groote L
AD  - Max Planck Institute of Psychiatry, Section of Neurochemistry, Munich, Germany. 
      Lott.de-Groote@bristol.ac.uk
FAU - Penalva, Rosana G
AU  - Penalva RG
FAU - Flachskamm, Cornelia
AU  - Flachskamm C
FAU - Reul, Johannes M H M
AU  - Reul JM
FAU - Linthorst, Astrid C E
AU  - Linthorst AC
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - J Neurochem
JT  - Journal of neurochemistry
JID - 2985190R
RN  - 0 (Biogenic Monoamines)
RN  - 0 (CRF receptor type 2)
RN  - 0 (Receptors, Corticotropin-Releasing Hormone)
RN  - 0 (Urocortins)
RN  - 0 (urocortin 2, mouse)
RN  - 5CLY6W2H1M (CRF receptor type 1)
RN  - 9015-71-8 (Corticotropin-Releasing Hormone)
SB  - IM
EIN - J Neurochem. 2005 Aug;94(3):862-4
MH  - Animals
MH  - Behavior, Animal/drug effects/*physiology
MH  - Biogenic Monoamines/*metabolism
MH  - Corticotropin-Releasing Hormone/administration & dosage
MH  - Humans
MH  - Injections, Intraventricular
MH  - Male
MH  - Mice
MH  - Neurosecretory Systems/drug effects/*metabolism
MH  - Rats
MH  - Rats, Wistar
MH  - Receptors, Corticotropin-Releasing Hormone/*agonists/metabolism
MH  - Urocortins
EDAT- 2005/06/15 09:00
MHDA- 2005/08/09 09:00
CRDT- 2005/06/15 09:00
PHST- 2005/06/15 09:00 [pubmed]
PHST- 2005/08/09 09:00 [medline]
PHST- 2005/06/15 09:00 [entrez]
AID - JNC3164 [pii]
AID - 10.1111/j.1471-4159.2005.03164.x [doi]
PST - ppublish
SO  - J Neurochem. 2005 Jul;94(1):45-56. doi: 10.1111/j.1471-4159.2005.03164.x.